HEDS is part of the School of Health and Related Research (ScHARR) at the University of Sheffield. We undertake research, teaching, training and consultancy on all aspects of health related decision science, with a particular emphasis on health economics, HTA and evidence synthesis.

Monday, 5 March 2012

Recent CUAs

Twice each month the CEA Registry Blog lists recently published cost utility studies and associated papers.  21 papers were listed this time. Here's a few in our areas of research interest:

Guillermin AL, Lloyd A, Best JH, Beth Deyoung M, Samyshkin Y, Aledort Gaebler J. Long-term cost-consequence analysis of exenatide once weekly versus sitagliptin or pioglitazone for the treatment of type 2 diabetes patients in the United States. J Med Econ. 2012 Feb 28. [Epub ahead of print] PubMed PMID: 22369345.

Alzahouri K, Bahrami S, Durand-Zaleski I, Guillemin F, Roux C. Cost-effectiveness of osteoporosis treatments in postmenopausal women using FRAX™ thresholds for decision. Joint Bone Spine. 2012 Feb 24. [Epub ahead of print] PubMed PMID: 22366150.

Lamond NW, Skedgel C, Rayson D, Lethbridge L, Younis T. Cost-utility of the 21-gene recurrence score assay in node-negative and node-positive breast cancer.  Breast Cancer Res Treat. 2012 Feb 24. [Epub ahead of print] PubMed PMID: 22361999.

Yang M, Rajan S, Issa AM. Cost effectiveness of gene expression profiling for early stage breast cancer: A decision-analytic model. Cancer. 2012 Feb 22. [Epub ahead of print] PubMed PMID: 22359236.